NasdaqGM:XOMA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	49	3	N/A	N/A	3
12/31/2025	36	-6	N/A	N/A	3
12/31/2024	29	-14	N/A	N/A	3
9/30/2024	22	-35	-15	-15	N/A
6/30/2024	15	-24	-8	-8	N/A
3/31/2024	6	-42	-13	-18	N/A
12/31/2023	5	-46	-18	-18	N/A
9/30/2023	4	-32	-18	-18	N/A
6/30/2023	4	-31	-20	-20	N/A
3/31/2023	3	-30	-14	-17	N/A
12/31/2022	6	-23	-13	-13	N/A
9/30/2022	40	10	42	22	N/A
6/30/2022	41	10	36	22	N/A
3/31/2022	41	12	36	23	N/A
12/31/2021	38	8	23	23	N/A
9/30/2021	30	1	-11	10	N/A
6/30/2021	29	6	-3	10	N/A
3/31/2021	29	6	-2	11	N/A
12/31/2020	29	9	10	10	N/A
9/30/2020	2	-13	-12	-12	N/A
6/30/2020	11	-9	-18	-5	N/A
3/31/2020	11	-10	-25	-6	N/A
12/31/2019	18	-2	-20	0	N/A
9/30/2019	20	-2	-18	1	N/A
6/30/2019	12	-8	-27	-5	N/A
3/31/2019	13	-6	-21	-6	N/A
12/31/2018	5	-13	-28	-13	N/A
9/30/2018	9	-11	-30	-15	N/A
6/30/2018	44	9	N/A	18	N/A
3/31/2018	53	18	N/A	13	N/A
12/31/2017	53	6	N/A	3	N/A
9/30/2017	48	-11	N/A	15	N/A
6/30/2017	12	-39	N/A	-28	N/A
3/31/2017	2	-61	N/A	-32	N/A
12/31/2016	6	-54	N/A	-34	N/A
9/30/2016	53	-11	N/A	-12	N/A
6/30/2016	55	1	N/A	-19	N/A
3/31/2016	57	-7	N/A	-23	N/A
12/31/2015	55	-21	N/A	-31	N/A
9/30/2015	12	-53	N/A	-77	N/A
6/30/2015	15	-67	N/A	-74	N/A
3/31/2015	18	-55	N/A	-74	N/A
12/31/2014	19	-38	N/A	-78	N/A
9/30/2014	27	-83	N/A	-68	N/A
6/30/2014	28	-99	N/A	-65	N/A
3/31/2014	29	-104	N/A	-60	N/A
12/31/2013	35	-124	N/A	-46	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XOMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: XOMA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XOMA is expected to become profitable in the next 3 years.

Revenue vs Market: XOMA's revenue (31.3% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: XOMA's revenue (31.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 06:22
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XOMA Royalty Corporation is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ritu Baral	Canaccord Genuity
Jason Kantor	Credit Suisse
Joseph Pantginis	H.C. Wainwright & Co.

XOMA Royalty Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 64%

Consensus revenue estimates fall by 58%

Consensus revenue estimates fall by 33%

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Recent updates

XOMA Royalty Corporation (NasdaqGM:XOMA) acquired Pulmokine, Inc. for $45 million.

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties

News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts

Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Consensus revenue estimates increase by 64%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue